Application of human induced pluripotent stem cell technology for cardiovascular regenerative pharmacology.
File(s)manuscript w figures. Majid et al..pdf (1.31 MB)
Accepted version
Author(s)
Type
Journal Article
Abstract
Cardiovascular diseases are one of the leading causes of mortality in the western world. Myocardial infarction is among the most prevalent and results in significant cell loss within the myocardium. Similarly, numerous drugs have been identified as having cardiotoxic side effects. The adult human heart is however unable to instigate an effective repair mechanism and regenerate the myocardium in response to such damage. This is in large part due to the withdrawal of cardiomyocytes (CMs) from the cell cycle. Thus, identifying, screening, and developing agents that could enhance the proliferative capacity of CMs holds great potential in cardiac regeneration. Human induced pluripotent stem cells (hiPSCs) and their cardiovascular derivatives are excellent tools in the search for such agents. This chapter outlines state-of-the art techniques for the two-dimensional differentiation and attainment of hiPSC-derived CMs and endothelial cells (ECs). Bioreactor systems and three-dimensional spheroids derived from hiPSC-cardiovascular derivatives are explored as platforms for drug discovery before focusing on relevant assays that can be employed to assess cell proliferation and viability.
Date Issued
2021-03-24
Date Acceptance
2021-03-01
Citation
Methods in Molecular Biology, 2021, 2454
ISSN
1064-3745
Publisher
Humana Press
Journal / Book Title
Methods in Molecular Biology
Volume
2454
Copyright Statement
© Springer Science+Business Media, LLC 2021. The final publication is available at Springer via https://doi.org/10.1007/7651_2021_369
Sponsor
Medical Research Council (MRC)
Imperial College Healthcare NHS Trust- BRC Funding
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/33755910
Grant Number
MR/R025002/1
RDF01
Subjects
3D spheroid cell culture
Cardiomyocytes
Cardiotoxicity
Endothelial cells
Human induced pluripotent stem cells (hiPSCs)
Regenerative pharmacology
Scalable manufacturing of hiPSC derivatives
Publication Status
Published
Coverage Spatial
United States
Date Publish Online
2021-03-24